By Daniel Webster, dWeb.News Publisher
BURLINGAME, Calif.–(BUSINESS WIRE)–Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that management will present and participate at multiple virtual investor conferences in September 2021. Details of the conferences are as follows:
Baird Global Healthcare Conference
Cameron Durrant, Chairman & CEO, will provide a corporate update at 5: 30pm EDT on September 14, 2021. The conference host will limit access to the conference on an invitation-only basis. For more information about accessing the meeting, please contact your Baird representative.
H.C. Wainwright 23rd Annual Global Investment Conference
Cameron Durrant, Chairman & CEO participated in a panel to discuss “Best Practices Planning for the Next Pandemic”, which was pre-recorded and will be available starting at 12pm EDT on September 15, 2021.
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Presentation date: September 22, 2021
Presentation time: 2: 05 ET
Webcast: Webcast link: https://wsw.com/webcast/oppenheimer16/hgen/2752454
The webcast will be archived for 90 days under the Investor Relations section of the company’s website at http://www.humanigen.com.
Cantor Global Healthcare 2021
Presentation date: September 27, 2021
Presentation time: 4: 40 ET
Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’. Lenzilumab is a first-in class antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). Preclinical studies have shown that GM-CSF acts as an upstream regulator for many inflammatory cytokines, chemokines, and other cytokine factors involved in the cytokine crisis. Early in the COVID-19 pandemic, investigation showed high levels of GM-CSF secreting T cells were associated with disease severity and intensive care unit admission. Humanigen’s Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent consequences of a full-blown cytokine storm in hospitalized patients with COVID-19. Humanigen submitted lenzilumab for a rolling review to the United Kingdom Medicines and Health Regulatory Agency. Humanigen is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 and, CD19-targeted CAR-T cell therapies, and exploring the effectiveness of lenzilumab in other inflammatory conditions such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation, eosinophilic asthma, and rheumatoid arthritis. Visit http://www.humanigen.com for more information. You can also follow Humanigen on Facebook, Twitter, LinkedIn and Facebook.
All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements are based on management’s current knowledge and assumptions. They also reflect management’s judgment and expectations about future performance or events. Management believes these statements are reasonable. However, they do not guarantee that they will be accurate. You should also be aware that actual events and results could differ materially from the forward-looking statements. Forward-looking statements include statements about lenzilumab’s development, approvals and plans, as well as words such “will”, “intend,”” “plan,” potential,” “potential,” goals, “accelerate,” and similar expressions.
Forward looking statements involve risks and uncertainties, including the possibility of losing profitability or needing additional capital to grow the business, our dependence on our partners for product development, and the uncertainties involved in the development, approvals, and launch of any new drug product.
Forward-looking statements should be accompanied by this cautionary note. Forward-looking statements should not be regarded as predictions of future events. Except as required by law, we are not obliged to revise and update any forward-looking statements in this presentation.
More dWeb.News Business News at https://dweb.news/news-sections/business-news/